>>10052031 PB

>The error was identified in the testing platform manufactured by a company known as Thermo Fisher Scientific

Thermo Fisher Chairman of the Board Marc Casper

Marc N. Casper , Chairman

Marc Casper has been president and chief executive officer of Thermo Fisher Scientific since October 2009. He was also elected chairman of the board in February 2020.

Mr. Casper joined Thermo Electron Corporation in 2001 as president of the Life Sciences sector. He was named senior vice president in 2003, and in 2005 assumed responsibility for all of the company’s operating divisions. After the merger that created Thermo Fisher Scientific in 2006, Mr. Casper was named executive vice president and president of its Analytical Technologies businesses, and in 2008 he became the company’s Chief Operating Officer.

Prior to joining Thermo Fisher, Mr. Casper served as president, chief executive officer and a director of Kendro Laboratory Products. Previously, he worked for clinical diagnostics provider Dade Behring Inc., serving as president–Americas. Mr. Casper began his career as a strategy consultant atBain & Company and later joined Bain Capital.

Mr. Casper serves on the boards of U.S. Bancorp,U.S. China Business Council, Brigham & Women’s Hospital and Wesleyan University. He was previously a director of the Advisory Board Company and Zimmer Holdings. Mr. Casper earned an MBA with high distinction from Harvard Business School and is a graduate of Wesleyan University, where he received a bachelor’s degree in economics.

US-China Business Council

US-China Business CouncilFormation 1973

Founded at Washington D.C.

Tax ID no.

23-7275160

Purpose To facilitate trade between China and the US

President

Craig B. Allen

Chairperson

Evan Greenburg

Website www.uschina.org

The US-China Business Council (USCBC) is a private, non-profit organisation aimed at promoting trade between the United States and China. It comprises around 200 American companies that trade and do business with China and receives around $13.9m in dues and other funding every year.[3][4]

https://www.usresistnews.org/resistance-resources/

USRESIST NEWS — A digital news service for learning about the impact of Trump administration policies and the organizations working to resist them

down at the bottom of the list of resources to resist TrumpUS-China Business Council

>>10053586

>Bain Capital

Trifecta with VP of Thermo Fisher

Thermo Fisher Vice President

Bain Capital

Bush Clinton Bush Hussein Secret Service

Experience

Thermo Fisher Scientific

Thermo Fisher Scientific

1 year 4 months

Vice President, Global Security and Real estate

Apr 2019 – Present1 year 4 months

Boston, Ma

Vice President Global Real Estate and Security

Apr 2019 – Present1 year 4 months

Waltham, Ma

Vice President, Global Real Estate and Securityl

Apr 2019 – Present1 year 4 months

Waltham, Ma

Bain Capital

Senior Vice President, Global Security & Facilities

Bain Capital

Oct 2012 – Present7 years 10 months

Boston, Ma

Bain Capital is a leading private, alternative asset management firm. With approximately $85 billion in assets under management, David is responsible for all physical and cyber security efforts for clients and employees.

David is a thought-leader, coordinating security efforts to ensure due diligence, appropriate risk management, and global crisis management. He works closely with the CIO and COO to establish cyber security and preventative measures, while also ensuring they are state of…

U.S. Secret Service

U.S. Secret Service

26 years

Assistant Director

2010 – 20122 years

Washington D.C. Metro Area

Special Agent in Charge

2002 – 20108 years

Washington D.C. Metro Area and Newark, NJ

Assistant to the Special Agent in Charge

1999 – 20023 years

Washington D.C. Metro Area

Special Agent

1986 – 199913 years

Washington D.C. Metro Area and Newark, NJ>>10053586

>>10053586

> Previously, he worked for clinical diagnostics provider Dade Behring Inc., serving as president–Americas

Dade Behring Inc

Dade Behring was a company which manufactured testing machinery and supplies for the medical diagnostics industry, based in Deerfield, Illinois and Glasgow, Delaware (formerly a DuPont site).

History

Behring Diagnostics, a Frankfurt-based[1] company bearing Dr. Emil von Behring's name, was spun off from Hoechst AG (which later became Aventis)in 1995. Soon after its formation, the company acquired a drug-testing firm called Syva Company and, in 1996, the diagnostics and clinical chemistry division of DuPont.[2]

Dade Behring was born from the merger of Behring Diagnostics and Deerfield, Illinois-based[1] Dade International,a private, independent company created by a group of investors led by Bain Capital[3]who had bought Baxter International's diagnostics unit for over $440 million, in late 1994. The combined operations of the two companies reached sales of $1.2 billion and employed a workforce of 6,400 worldwide.

The new firm became the world's largest company devoted to diagnostics, with sales of over $500 million. The "Dade" part of the name is a legacy of the Dade Reagents Company, founded by Dr. John Elliott near the end of the 1940s to provide consistent, high quality typing and testing of blood.

Hoechst AG

History

The company was founded in 1863 as "Teerfarbenfabrik Meister, Lucius & Co." in Höchst, near Frankfurt and changed its name some years later to "Teerfarbenfabrik Meister Lucius & Brüning". In 1880 it became a stock company "Farbwerke vorm. Meister Lucius & Brüning AG". For the international market the name was simplified to "Farbwerke Hoechst AG". Until 1925 the Hoechst AG was independent. In 1916, the Hoechst AG was one of the co-founders of IG Farben, an advocacy group of Germany's chemicals industry to gain industrial power during and after World War I. In 1925, IG Farben turned from an advocacy group into the well-known conglomerate.

World War II

Various Hoechst facilities were bombed during the Oil Campaign of World War II. Its managers in charge were prosecuted along with other IG Farben managers—during the Nuremberg trials—in the IG Farben trial for their role in the exploitation of enslaved laborers and for testing drugs on concentration camp prisoners.[1]

>>10053634

>>10053582

>>10053582

>Connecticut State Public Health Lab Discovers False Positive COVID-19 Test Results

>>10053586

>>10053634

>>10053698

>>10053634

>>10053698

>http://homenewshere.com/news/state/article_fa5aa8cb-2744-5b54-b243-212ee611df4d.html

Thermo Fisher Scientific Reports Second Quarter 2020 Results

By Thermo Fisher Scientific Jul 22, 2020 Updated 23 hrs ago

WALTHAM, Mass., July 22, 2020 /PRNewswire/ – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2020.

Second Quarter 2020 Highlights

Second quarter revenue increased 10% to $6.92 billion.

Second quarter GAAP diluted earnings per share (EPS) increased 5% to $2.90.

Second quarter adjusted EPS increased 28% to $3.89.

Leveraged our industry-leading scale and expertise to meet strong global demand for COVID-19 products and services. Highlights in the second quarter included:

Generated approximately $1.3 billion of COVID-related revenue

Received expansion of emergency use authorization (EUA) to run our PCR test on additional instruments and consumables for greater workflow flexibility

Designed and built a new facility in Lenexa, Kansas, to manufacture highly specialized viral transport media (VTM) for sample collection under a U.S. government contract

Formed a collaboration with WuXi Diagnostics and Mayo Clinicto develop a total antibodies serology test

Secured a multi-year pharma services contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support accelerated vaccine development and production.

>https://www.prnewswire.com/news-releases/wuxi-diagnostics-to-open-its-first-research-facility-in-the-us-300921555.html

WuXi Diagnostics

About WuXi Diagnostics

WuXi Diagnostics is a joint venture formed in 2018 betweenWuXi AppTec Groupand Mayo Clinic. The company's mission is to build an innovative model that enables diagnostic product innovation, generates clinical insights, benefits the health of mankind through precision diagnosis and treatment, and ultimately fulfills the vision of "every disease can be precisely diagnosed." For more information, please visit：www.wuxidiagnostics.com/en.

SOURCE WuXi Diagnostics

WuXi AppTec Group

>https://www.wuxiapptec.com/about/history

WuXi Apptec history

2000

WuXi PharmaTech was registered in the city of Wuxi, Jiangsu and operated in Shanghai

2001

WuXi started synthetic chemistry services

2003

WuXi started manufacturing process development services

2004

WuXi started manufacturing services for research and development

2005

WuXi started bio-analytical services

2006

WuXi started antibody discovery and process development services

2007

WuXi started toxicology and formulation services

The Tianjin site of WuXi was put into operation and it was among the leading R&D bases of chemical medicines in China then

WuXi PharmaTech traded on the New York Stock Exchange under the ticker symbol "NYSE:WX"

WuXi set up "Life Science and Chemistry Awards", aiming to stimulate early-stage innovation and promote excellence in life sciences and clinical research

2008

WuXi PharmaTech acquired AppTec Laboratory Services, with locations in Minnesota, Pennsylvania and Georgia. The Company has been renamed WuXi AppTec since then.

>>10053754

rest of WuXi timeline

2009

WuXi opened a toxicology facility in Suzhou, which became the most important base of toxicology services

2010

SynTheAll Pharmaceutical (STA) opened a large-scale manufacturing facility in Jinshan District, Shanghai

2011

WuXi acquired Medkey, expanding to clinical development and registration services

2012

The R&D and manufacturing site in the city of Wuxi was put into operation

Wuhan site was put into operation, and it became the key of WuXi's strategic network in central and western China

2014

WuXi AppTec opened a new facility in Philadelphia, Pennsylvania, strengthening R&D and production services of CAR-T therapies and other immunotherapies

WuXi Laboratory Testing Division expanded with acquisition of XenoBiotic Laboratories in Plainsboro, New Jersey, bolstering LTD's bioanalytical and DMPK/ADME services for U.S. customers

2015

SynTheAll Pharmaceutical (STA) listed its shares on the New Third Board

WuXi launched medical device testing services in China

2016

WuXi acquired Crelux, enhancing WuXi's structure-based drug discovery capabilities in Europe

STA began operations at a new, fully integrated R&D and cGMP manufacturing site in Changzhou

2017

WuXi set up Advanced Therapy Unit in Philadelphia, Pennsylvania, enhancing U.S.-based cell and gene therapies

WuXi acquired HD Biosciences in San Diego, California, strengthening U.S. biology R&D capacity and capability

WuXi acquired ResearchPoint Global in Austin, Texas, expanding U.S. clinical research capabilities

2018

WuXi built up its Life Science Industry Park in Chengdu

WuXi AppTec announced listing of Initial Public Offering of Common Stock on the Shanghai Stock Exchange (stock code: 603259.SH)

WuXi AppTec listed H shares on the Hong Kong Stock Exchange (stock code: 2359.HK)

2019

The first WuXi Healthcare Forum held in Shanghai

WuXi AppTec acquired Pharmapace in San Diego, California, to enhance biometrics services for clinical development